AMARIN CORP PLC\UK
Close on Oct 19, 2026
- Market cap
- $4.80B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Oct 28, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 29, 2026 | During market hours | $42.20M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 29, 2026 | Before market open | $45.10M | $-0.03 | $0.00 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 25, 2026 | Before market open | $49.20M | $0.00 | $0.01 |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 29, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 30, 2025 | Before market open | $72.70M | $-0.03 | $0.04 |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | Before market open | $42.00M | $-0.04 | $-0.02 |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 12, 2025 | Before market open | $62.30M | $-0.12 | $-0.02 |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 30, 2024 | During market hours | $42.30M | $-0.06 | $-0.05 |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 31, 2024 | Before market open | $67.50M | $0.00 | $0.01 |
| Q1 FY2024 Ended Mar 31, 2024 | May 1, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 29, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Jul 29, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| cash | December 31, 2026 | 10% growth | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Amarin Corp Plc\Uk filed with the SEC
Amarin Reports 2026 First Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
Amarin Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Amarin Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Amarin Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
AMARIN ANNOUNCES EXCLUSIVE LICENSE AND SUPPLY AGREEMENT WITH RECORDATI TO COMMERCIALIZE VAZKEPA® (ICOSAPENT ETHYL) IN EUROPE
Material agreement · Exit or restructuring costs · Regulation FD disclosure · EX-99.1 to Form 8-K
Amarin Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change
Regulation FD disclosure · EX-99.1 to Form 8-K
Amarin Reports Fourth Quarter Financial Results & Business Update and Announces Important Corporate Action
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
AMARIN BOARD OF DIRECTORS ANNOUNCES CEO TRANSITION
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Amarin Reports First Quarter 2024 Business Update and Financial Results
Results of operations · EX-99.1 to Form 8-K
Amarin Announces Results of Annual General Meeting of Shareholders
Executive or director change · Shareholder vote results · Other events · EX-99.1 to Form 8-K
Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe
Other events · EX-99.1 to Form 8-K
Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
AMARIN PROVIDES PRELIMINARY FOURTH QUARTER 2023 SELECTED FINANCIALS AND OUTLINES KEY PRIORITIES FOR 2024
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
JANUARY 2024 42nd Annual J.P. Morgan Healthcare Conference Patrick Holt President & CEO
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Amarin Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
AMARIN APPOINTS JONATHAN PROVOOST EXECUTIVE VICE PRESIDENT, CHIEF LEGAL & COMPLIANCE OFFICER
Other events · EX-99.1 to Form 8-K
Amarin Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Amarin Implements Organizational Restructuring to Strengthen the Company While Driving Patient
Results of operations · Exit or restructuring costs · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Amarin Appoints Patrick Holt as President and Chief Executive Officer
Results of operations · Exit or restructuring costs · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Amarin Reports First Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99 to Form 8-K
AMARIN NAMES AARON BERG INTERIM PRESIDENT & CHIEF EXECUTIVE OFFICER AND ADDS OLIVER O’CONNOR TO COMPANY’S BOARD OF DIRECTORS
Executive or director change · Regulation FD disclosure · EX-99 to Form 8-K
EX-99.1 to Form 8-K
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Results of operations · EX-99 to Form 8-K
On behalf of Amarin Corporation plc
Other events · EX-99.1 to Form 8-K
AMARIN PROVIDES PRELIMINARY FOURTH QUARTER AND FULL
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Mikhail President & CEO January 23
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Amarin Board of Directors Announces Appointment of Murray W. Stewart, DM FRCP.
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
16, 2022 Karim Mikhail President & CEO Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Amarin Reports Third Quarter 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
AMARIN APPOINTS ADAM BERGER AND GERALDINE MURPHY TO BOARD OF DIRECTORS
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Amarin Provides Update on VAZKEPA ® (icosapent
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Amarin Reports Second Quarter 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
AMARIN ANNOUNCES COMPREHENSIVE COST REDUCTION PLAN TO ADDRESS MARKET DYNAMICS IN U.S. BUSINESS
Exit or restructuring costs · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K